JPRN-UMIN000020440
Completed
Phase 1
A combination immunotherapy for the patients with advanced or metastatic solid cancer - A combination immunotherapy for the patients with advanced or metastatic solid cancer
Yamaguchi university Graduate School of Medicine0 sites17 target enrollmentFebruary 1, 2016
Conditionssolid cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- solid cancer
- Sponsor
- Yamaguchi university Graduate School of Medicine
- Enrollment
- 17
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Uncontroled general complication. etc
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)Immune thrombocytopeniaMedDRA version: 23.0Level: PTClassification code: 10083842Term: Immune thrombocytopenia Class: 100000004851Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]Therapeutic area: Diseases [C] - Immune System Diseases [C20]CTIS2023-505788-35-00Fakultni Nemocnice Hradec Kralove73
Recruiting
Phase 2
Combined sublingual immunotherapy VALERGEN-DP and VALERGEN-BT-Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000240ational Center of Bioproducts (BIOCEN)120
Completed
Phase 1
A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancercolorectal cancerJPRN-UMIN000022082Yamaguchi University12
Recruiting
Not Applicable
Safety and efficacy of combination immunotherapy with nivolumab and ipilimumab for elderly lung cancer patients: a cohort studyJPRN-UMIN000046353ational Hospital Organization Kyoto Medical Center60
Completed
Not Applicable
Combined therapy with immune-suppressive drug in children with immunoglobulin resistant Kawasaki diseaseKawasaki diseaseJPRN-UMIN000032096Dokkyo medical university52